Scientific article
Open access

Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study

Published inBMC infectious diseases, vol. 15, 382
Publication date2015-09-21
First online date2015-09-21

Background: Temporary increases in plasma HIV RNA ('blips') are common in HIV patients on combination antiretroviral therapy (cART). Blips above 500 copies/mL have been associated with subsequent viral rebound. It is not clear if this relationship still holds when measurements are made using newer more sensitive assays.

Methods: We selected antiretroviral-naive patients that then recorded one or more episodes of viral suppression on cART with HIV RNA measurements made using more sensitive assays (lower limit of detection below 50 copies/ml). We estimated the association in these episodes between blip magnitude and the time to viral rebound.

Results: Four thousand ninety-four patients recorded a first episode of viral suppression on cART using more sensitive assays; 1672 patients recorded at least one subsequent suppression episode. Most suppression episodes (87 %) were recorded with TaqMan version 1 or 2 assays. Of the 2035 blips recorded, 84 %, 12 % and 4 % were of low (50-199 copies/mL), medium (200-499 copies/mL) and high (500-999 copies/mL) magnitude respectively. The risk of viral rebound increased as blip magnitude increased with hazard ratios of 1.20 (95 % CI 0.89-1.61), 1.42 (95 % CI 0.96-2.19) and 1.93 (95 % CI 1.24-3.01) for low, medium and high magnitude blips respectively; an increase of hazard ratio 1.09 (95 % CI 1.03 to 1.15) per 100 copies/mL of HIV RNA.

Conclusions: With the more sensitive assays now commonly used for monitoring patients, blips above 200 copies/mL are increasingly likely to lead to viral rebound and should prompt a discussion about adherence.

  • Adult
  • Anti-HIV Agents / therapeutic use
  • Cohort Studies
  • Female
  • HIV Infections / diagnosis
  • HIV Infections / drug therapy
  • HIV Infections / virology
  • Humans
  • Male
  • Middle Aged
  • Proportional Hazards Models
  • RNA, Viral / blood
  • Risk
  • Viral Load
  • Viremia / diagnosis
  • Viremia / virology
Research group
Citation (ISO format)
YOUNG, Jim et al. Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study. In: BMC infectious diseases, 2015, vol. 15, p. 382. doi: 10.1186/s12879-015-1120-8
Main files (1)
Article (Published version)
ISSN of the journal1471-2334

Technical informations

Creation02/07/2023 8:41:39 AM
First validation11/20/2023 9:38:18 AM
Update time11/20/2023 9:38:18 AM
Status update11/20/2023 9:38:18 AM
Last indexation05/06/2024 5:24:32 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack